cabergoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
ergot alkaloid derivatives 460 81409-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cabergoline
  • dostinex
  • galastop
  • cabaser
  • cabaseril
An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.
  • Molecular weight: 451.62
  • Formula: C26H37N5O2
  • CLOGP: 4.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 71.68
  • ALOGS: -3.85
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,KDR,KIT,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 44
kinase-selectivity-class AXL,BRAF,CAMK2D,CDK4,EGFR,EIF2AK3,SIK2,STK33,TEK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1996 FDA
Aug. 1, 1999 PMDA PFIZER JAPAN INC.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood growth hormone increased 188.62 18.25 35 10051 495 90617866
Pulmonary pain 188.00 18.25 53 10033 5061 90613300
Amyloid arthropathy 185.68 18.25 42 10044 1638 90616723
Insulin-like growth factor decreased 151.69 18.25 28 10058 384 90617977
Insulin-like growth factor increased 150.17 18.25 32 10054 942 90617419
Aortic valve incompetence 120.57 18.25 40 10046 6584 90611777
Ovarian hyperstimulation syndrome 109.10 18.25 36 10050 5826 90612535
Pituitary tumour 90.72 18.25 21 10065 908 90617453
Blood prolactin increased 86.85 18.25 27 10059 3610 90614751
Needle issue 78.82 18.25 36 10050 13898 90604463
Coronary artery dissection 69.41 18.25 17 10069 937 90617424
Empty sella syndrome 69.11 18.25 11 10075 57 90618304
Blood prolactin decreased 68.49 18.25 11 10075 61 90618300
Cerebrospinal fluid leakage 61.04 18.25 17 10069 1550 90616811
Mitral valve incompetence 57.21 18.25 34 10052 22490 90595871
Gambling disorder 55.33 18.25 15 10071 1237 90617124
Pituitary apoplexy 53.84 18.25 10 10076 142 90618219
Drug abuse 52.83 18.25 55 10031 82292 90536069
Pituitary haemorrhage 51.93 18.25 9 10077 84 90618277
Pituitary tumour benign 51.63 18.25 16 10070 2116 90616245
Hemianopia heteronymous 50.02 18.25 8 10078 43 90618318
Cardiac valve disease 46.47 18.25 18 10068 4617 90613744
Inappropriate schedule of product administration 44.35 18.25 68 10018 149865 90468496
Blood pressure increased 44.29 18.25 79 10007 197138 90421223
Prolactin-producing pituitary tumour 44.02 18.25 8 10078 100 90618261
Intentional product misuse 43.94 18.25 52 10034 89552 90528809
Diabetes mellitus 42.81 18.25 44 10042 64831 90553530
Tricuspid valve incompetence 41.82 18.25 25 10061 16706 90601655
Product administration error 40.35 18.25 29 10057 26394 90591967
Delusion 38.06 18.25 22 10064 13818 90604543
Acromegaly 37.85 18.25 7 10079 97 90618264
Compulsive shopping 37.70 18.25 10 10076 759 90617602
Hyperprolactinaemia 37.03 18.25 16 10070 5417 90612944
Adrenocortical insufficiency acute 36.76 18.25 13 10073 2588 90615773
Hypogonadism 36.68 18.25 7 10079 116 90618245
Bite 36.41 18.25 9 10077 515 90617846
Mediastinal fibrosis 35.79 18.25 6 10080 45 90618316
Benign neoplasm of adrenal gland 35.67 18.25 6 10080 46 90618315
Cholelithiasis 35.34 18.25 36 10050 52470 90565891
Infusion related reaction 35.26 18.25 3 10083 416777 90201584
Pneumocephalus 31.21 18.25 7 10079 262 90618099
Abortion spontaneous 30.94 18.25 34 10052 54022 90564339
Injection site mass 30.91 18.25 23 10063 22067 90596294
Adenoma benign 30.89 18.25 9 10077 965 90617396
Hypothalamo-pituitary disorder 30.86 18.25 11 10075 2241 90616120
Impulse-control disorder 30.81 18.25 9 10077 973 90617388
Urine calcium/creatinine ratio increased 30.51 18.25 6 10080 117 90618244
Tonsillar inflammation 30.32 18.25 6 10080 121 90618240
Nocturia 30.07 18.25 17 10069 10238 90608123
Brain neoplasm 28.87 18.25 13 10073 4851 90613510
Obesity 28.61 18.25 46 10040 105461 90512900
Nervousness 27.88 18.25 26 10060 34030 90584331
Mastitis 27.81 18.25 11 10075 2982 90615379
Neoplasm progression 27.24 18.25 29 10057 44457 90573904
Blindness 27.16 18.25 23 10063 26545 90591816
Infection 27.12 18.25 4 10082 362090 90256271
Visual field defect 26.92 18.25 14 10072 7152 90611209
Neoplasm 26.76 18.25 15 10071 8888 90609473
Overweight 26.41 18.25 13 10073 5921 90612440
Knee arthroplasty 26.39 18.25 39 10047 83143 90535218
Urethral caruncle 26.02 18.25 5 10081 86 90618275
Menstrual disorder 25.99 18.25 13 10073 6125 90612236
Sleep apnoea syndrome 25.54 18.25 24 10062 31723 90586638
Injection site hypertrophy 25.45 18.25 5 10081 97 90618264
Camptocormia 25.32 18.25 6 10080 287 90618074
Aortic valve sclerosis 24.81 18.25 8 10078 1202 90617159
Hormone level abnormal 24.75 18.25 10 10076 2863 90615498
Death 24.64 18.25 10 10076 456541 90161820
Retroperitoneal fibrosis 24.37 18.25 6 10080 338 90618023
Blood pressure systolic increased 23.98 18.25 31 10055 58314 90560047
Panic disorder 23.97 18.25 10 10076 3105 90615256
Soft tissue mass 23.73 18.25 6 10080 377 90617984
Blood growth hormone abnormal 23.63 18.25 4 10082 32 90618329
Drug dependence 23.26 18.25 22 10064 29305 90589056
Blood parathyroid hormone increased 23.02 18.25 10 10076 3427 90614934
Trichoglossia 22.60 18.25 6 10080 457 90617904
Secondary hypogonadism 22.59 18.25 5 10081 176 90618185
Dopamine dysregulation syndrome 22.46 18.25 5 10081 181 90618180
Kounis syndrome 22.39 18.25 9 10077 2544 90615817
Chikungunya virus infection 22.27 18.25 5 10081 188 90618173
Product dose omission issue 22.07 18.25 77 10009 291610 90326751
Application site mass 21.86 18.25 4 10082 52 90618309
Encephalocele 21.85 18.25 5 10081 205 90618156
Ovarian rupture 21.79 18.25 4 10082 53 90618308
Reversible cerebral vasoconstriction syndrome 21.26 18.25 10 10076 4120 90614241
Adrenal disorder 21.16 18.25 8 10078 1922 90616439
Body temperature decreased 21.09 18.25 19 10067 23797 90594564
Overdose 21.01 18.25 51 10035 157658 90460703
Blood thyroid stimulating hormone decreased 20.95 18.25 11 10075 5729 90612632
Injection site pain 20.86 18.25 54 10032 173645 90444716
Drug hypersensitivity 20.75 18.25 13 10073 463596 90154765
Hair disorder 20.73 18.25 7 10079 1214 90617147
Polyp 20.62 18.25 12 10074 7632 90610729
Hand deformity 20.59 18.25 4 10082 296358 90322003
Blood sodium increased 20.48 18.25 9 10077 3173 90615188
Cerebrospinal fistula 20.15 18.25 3 10083 9 90618352
Injection site haemorrhage 20.12 18.25 20 10066 28298 90590063
Galactorrhoea 20.09 18.25 10 10076 4662 90613699
Pneumonia 20.02 18.25 25 10061 638034 89980327
Toxicity to various agents 19.75 18.25 4 10082 287842 90330519
Pituitary tumour recurrent 19.63 18.25 4 10082 94 90618267
Blood gonadotrophin decreased 19.48 18.25 3 10083 12 90618349
Anxiety 19.44 18.25 77 10009 309695 90308666
Drug resistance 18.91 18.25 20 10066 30429 90587932
Mitral valve disease 18.90 18.25 8 10078 2574 90615787
Arteriovenous fistula 18.88 18.25 5 10081 377 90617984
Joint swelling 18.82 18.25 17 10069 503283 90115078
Blood glucose increased 18.65 18.25 36 10050 95210 90523151
Dengue fever 18.65 18.25 6 10080 896 90617465
Stomatitis 18.47 18.25 4 10082 274694 90343667
Multiple endocrine neoplasia Type 1 18.34 18.25 3 10083 19 90618342
Hypopituitarism 18.26 18.25 7 10079 1746 90616615

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrospinal fluid leakage 464.00 20.64 82 6212 636 42614405
Gambling disorder 181.81 20.64 44 6250 1732 42613309
Insulin-like growth factor increased 180.33 20.64 43 6251 1588 42613453
Pneumocephalus 137.24 20.64 24 6270 173 42614868
Radiation inflammation 102.32 20.64 25 6269 1023 42614018
Aortic valve incompetence 95.28 20.64 36 6258 6512 42608529
Blood growth hormone increased 92.47 20.64 21 6273 623 42614418
Pulmonary pain 92.17 20.64 25 6269 1553 42613488
Visual pathway disorder 87.40 20.64 13 6281 26 42615015
Needle issue 85.26 20.64 36 6258 8691 42606350
Secondary hypogonadism 78.01 20.64 19 6275 767 42614274
Mitral valve incompetence 71.71 20.64 39 6255 16450 42598591
Pituitary haemorrhage 65.36 20.64 13 6281 200 42614841
Prolactin-producing pituitary tumour 60.82 20.64 10 6284 47 42614994
Andropause 60.24 20.64 11 6283 104 42614937
Irritable bowel syndrome 58.34 20.64 23 6271 4658 42610383
Empty sella syndrome 52.61 20.64 9 6285 56 42614985
Cardiac valve disease 50.40 20.64 19 6275 3412 42611629
Hormone level abnormal 49.66 20.64 12 6282 468 42614573
Pituitary tumour 47.24 20.64 12 6282 576 42614465
Genital pain 46.58 20.64 13 6281 897 42614144
Lung neoplasm malignant 43.74 20.64 30 6264 19117 42595924
Genital ulceration 42.30 20.64 12 6282 879 42614162
Chiasma syndrome 42.29 20.64 6 6288 7 42615034
Jealous delusion 41.07 20.64 10 6284 403 42614638
Neoplasm progression 40.80 20.64 34 6260 28966 42586075
Schizophrenia 40.51 20.64 23 6271 10527 42604514
Acromegaly 40.20 20.64 7 6287 49 42614992
Intracranial hypotension 40.19 20.64 10 6284 441 42614600
Carcinoid tumour 39.85 20.64 9 6285 260 42614781
Pituitary apoplexy 39.81 20.64 8 6286 130 42614911
Injection site erosion 39.75 20.64 8 6286 131 42614910
Impulse-control disorder 39.55 20.64 13 6281 1562 42613479
Hyperprolactinaemia 39.51 20.64 14 6280 2109 42612932
Arthropathy 38.15 20.64 33 6261 29564 42585477
Postprandial hypoglycaemia 36.96 20.64 7 6287 82 42614959
Food poisoning 36.20 20.64 14 6280 2692 42612349
Priapism 35.99 20.64 18 6276 6389 42608652
Therapeutic response decreased 35.53 20.64 35 6259 36977 42578064
Oncologic complication 35.00 20.64 9 6285 454 42614587
Hypersexuality 34.65 20.64 12 6282 1690 42613351
Tricuspid valve incompetence 34.20 20.64 21 6273 11092 42603949
Cortisol free urine increased 33.96 20.64 5 6289 9 42615032
Pleural fibrosis 33.13 20.64 11 6283 1363 42613678
Performance enhancing product use 32.78 20.64 7 6287 155 42614886
Crystal arthropathy 32.46 20.64 6 6288 61 42614980
Pituitary tumour benign 32.29 20.64 10 6284 992 42614049
Renal haematoma 31.92 20.64 9 6285 645 42614396
Injection site injury 31.78 20.64 8 6286 370 42614671
Blood testosterone increased 31.72 20.64 11 6283 1556 42613485
Glucose tolerance decreased 31.55 20.64 6 6288 72 42614969
Gambling 30.90 20.64 7 6287 205 42614836
Knee arthroplasty 30.67 20.64 18 6276 8763 42606278
Death 30.29 20.64 16 6278 471169 42143872
Gastrointestinal pain 29.60 20.64 14 6280 4401 42610640
IIIrd nerve paralysis 28.51 20.64 8 6286 563 42614478
Pleural effusion 28.13 20.64 51 6243 97115 42517926
Fibrosis 27.93 20.64 12 6282 3018 42612023
Blood prolactin increased 27.61 20.64 11 6283 2287 42612754
Intestinal metastasis 27.26 20.64 7 6287 351 42614690
Blood corticotrophin increased 27.03 20.64 6 6288 160 42614881
Borderline personality disorder 25.84 20.64 7 6287 432 42614609
Aortic valve disease 25.38 20.64 9 6285 1358 42613683
Hemianopia 24.64 20.64 8 6286 924 42614117
Lactose intolerance 24.53 20.64 9 6285 1497 42613544
Injection site pain 24.41 20.64 36 6258 57762 42557279
Autoimmune thyroiditis 24.10 20.64 9 6285 1573 42613468
Dopamine dysregulation syndrome 24.00 20.64 7 6287 566 42614475
Cerebrospinal fistula 23.96 20.64 4 6290 21 42615020
Anaemia 23.90 20.64 6 6288 280272 42334769
Inflammation 23.58 20.64 27 6267 33820 42581221
Heart rate decreased 23.55 20.64 28 6266 36504 42578537
Drug abuse 23.05 20.64 49 6245 104722 42510319
Dementia 22.50 20.64 19 6275 16461 42598580
Blood testosterone decreased 22.43 20.64 12 6282 4890 42610151
Blood cholesterol abnormal 22.15 20.64 9 6285 1970 42613071
Drug resistance 21.66 20.64 26 6268 34222 42580819
Blood pressure increased 21.65 20.64 47 6247 101881 42513160
Metastases to pelvis 21.39 20.64 6 6288 422 42614619
Intentional product misuse 21.19 20.64 35 6259 61865 42553176

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrospinal fluid leakage 457.37 16.55 95 14592 2053 110572559
Pulmonary pain 276.86 16.55 78 14609 6215 110568397
Insulin-like growth factor increased 262.64 16.55 61 14626 2235 110572377
Blood growth hormone increased 231.79 16.55 48 14639 1020 110573592
Gambling disorder 187.27 16.55 46 14641 2145 110572467
Amyloid arthropathy 178.27 16.55 42 14645 1638 110572974
Aortic valve incompetence 164.60 16.55 60 14627 10921 110563691
Pneumocephalus 159.75 16.55 31 14656 467 110574145
Needle issue 149.46 16.55 64 14623 17776 110556836
Insulin-like growth factor decreased 135.64 16.55 28 14659 585 110574027
Pituitary haemorrhage 108.93 16.55 21 14666 305 110574307
Mitral valve incompetence 106.19 16.55 62 14625 33267 110541345
Radiation inflammation 104.93 16.55 25 14662 1023 110573589
Blood prolactin increased 103.00 16.55 34 14653 4608 110570004
Ovarian hyperstimulation syndrome 102.09 16.55 35 14652 5325 110569287
Pituitary tumour 100.49 16.55 25 14662 1228 110573384
Empty sella syndrome 97.32 16.55 17 14670 137 110574475
Prolactin-producing pituitary tumour 90.01 16.55 16 14671 144 110574468
Pituitary apoplexy 85.18 16.55 17 14670 298 110574314
Secondary hypogonadism 83.37 16.55 20 14667 843 110573769
Visual pathway disorder 81.88 16.55 14 14673 98 110574514
Acromegaly 77.61 16.55 14 14673 138 110574474
Hyperprolactinaemia 77.01 16.55 30 14657 6545 110568067
Cardiac valve disease 74.15 16.55 29 14658 6392 110568220
Drug abuse 72.71 16.55 103 14584 177308 110397304
Pituitary tumour benign 71.88 16.55 23 14664 2824 110571788
Intentional product misuse 69.59 16.55 87 14600 132817 110441795
Tricuspid valve incompetence 67.17 16.55 41 14646 23832 110550780
Blood pressure increased 63.55 16.55 119 14568 258254 110316358
Coronary artery dissection 61.89 16.55 17 14670 1231 110573381
Andropause 61.40 16.55 11 14676 104 110574508
Knee arthroplasty 59.34 16.55 57 14630 64891 110509721
Hormone level abnormal 59.16 16.55 19 14668 2361 110572251
Intracranial hypotension 57.59 16.55 14 14673 624 110573988
Chiasma syndrome 50.16 16.55 7 14680 8 110574604
Neoplasm progression 48.55 16.55 51 14636 64544 110510068
Diabetes mellitus 45.65 16.55 61 14626 99320 110475292
Delusion 43.02 16.55 31 14656 23724 110550888
Genital pain 42.41 16.55 13 14674 1387 110573225
Blood growth hormone abnormal 42.02 16.55 7 14680 41 110574571
Toxicity to various agents 41.46 16.55 7 14680 480548 110094064
Visual field defect 40.96 16.55 22 14665 10050 110564562
Product dose omission issue 39.78 16.55 113 14574 321669 110252943
Drug resistance 39.70 16.55 43 14644 56331 110518281
Priapism 39.33 16.55 18 14669 5843 110568769
Death 39.32 16.55 22 14665 698847 109875765
Postprandial hypoglycaemia 38.99 16.55 8 14679 162 110574450
Acute kidney injury 38.73 16.55 18 14669 635412 109939200
Injection site erosion 38.23 16.55 8 14679 179 110574433
Blood testosterone increased 38.18 16.55 12 14675 1390 110573222
Dopamine dysregulation syndrome 37.97 16.55 10 14677 617 110573995
Gambling 37.90 16.55 9 14678 363 110574249
Injection site pain 37.69 16.55 77 14610 177845 110396767
Cerebrospinal fistula 37.34 16.55 6 14681 27 110574585
Inappropriate schedule of product administration 37.22 16.55 83 14604 203554 110371058
Hemianopia heteronymous 37.10 16.55 7 14680 90 110574522
Impulse-control disorder 36.67 16.55 13 14674 2181 110572431
Infusion related reaction 36.54 16.55 4 14683 381158 110193454
Reversible cerebral vasoconstriction syndrome 36.34 16.55 16 14671 4745 110569867
Neoplasm 36.30 16.55 21 14666 11066 110563546
Oncologic complication 36.00 16.55 9 14678 451 110574161
Jealous delusion 35.75 16.55 9 14678 464 110574148
Blindness 35.28 16.55 33 14654 36326 110538286
Adenoma benign 34.77 16.55 11 14676 1302 110573310
Mediastinal fibrosis 34.73 16.55 6 14681 45 110574567
Mitral valve disease 34.44 16.55 14 14673 3411 110571201
Genital ulceration 34.15 16.55 12 14675 1963 110572649
Carcinoid tumour 33.70 16.55 9 14678 586 110574026
Syndactyly 33.60 16.55 7 14680 153 110574459
Bite 33.26 16.55 9 14678 616 110573996
Performance enhancing product use 33.06 16.55 7 14680 166 110574446
Benign neoplasm of adrenal gland 33.00 16.55 6 14681 62 110574550
Obesity 32.68 16.55 56 14631 113295 110461317
Glucose tolerance decreased 31.96 16.55 6 14681 75 110574537
Lung neoplasm malignant 31.47 16.55 30 14657 33812 110540800
Pleural fibrosis 31.34 16.55 14 14673 4294 110570318
Pneumonia 30.79 16.55 43 14644 876671 109697941
Aortic valve sclerosis 30.76 16.55 11 14676 1892 110572720
Hypersexuality 30.56 16.55 11 14676 1929 110572683
Compulsive shopping 30.34 16.55 9 14678 859 110573753
Overdose 29.75 16.55 83 14604 233711 110340901
Heart rate decreased 29.46 16.55 45 14642 82711 110491901
Cardiomegaly 29.35 16.55 27 14660 29103 110545509
Body temperature decreased 29.25 16.55 30 14657 36905 110537707
Renal haematoma 29.23 16.55 9 14678 974 110573638
Injection site mass 29.15 16.55 25 14662 24588 110550024
Rheumatoid arthritis 29.08 16.55 3 14684 299610 110275002
Aortic valve disease 29.08 16.55 11 14676 2216 110572396
Brain neoplasm 29.06 16.55 15 14672 6322 110568290
Blood prolactin decreased 29.04 16.55 7 14680 301 110574311
Drug hypersensitivity 29.01 16.55 12 14675 454078 110120534
Sleep apnoea syndrome 28.73 16.55 31 14656 40416 110534196
Febrile neutropenia 28.71 16.55 4 14683 316763 110257849
Pituitary enlargement 28.31 16.55 6 14681 143 110574469
Urine calcium/creatinine ratio increased 28.07 16.55 6 14681 149 110574463
Adrenocortical insufficiency acute 27.81 16.55 13 14674 4427 110570185
Hallucination 27.79 16.55 49 14638 101383 110473229
Schizophrenia 27.55 16.55 23 14664 21803 110552809
Brain herniation 26.94 16.55 16 14671 8847 110565765
Lower respiratory tract infection 26.80 16.55 82 14605 243024 110331588
Tonsillar inflammation 26.64 16.55 6 14681 191 110574421
Hypothalamo-pituitary disorder 26.46 16.55 11 14676 2835 110571777
Food poisoning 26.14 16.55 14 14673 6358 110568254
Urethral caruncle 26.04 16.55 5 14682 71 110574541
Tricuspid valve disease 25.99 16.55 7 14680 471 110574141
Stomatitis 25.48 16.55 3 14684 270239 110304373
Carotid aneurysm rupture 25.27 16.55 4 14683 16 110574596
Blood pressure systolic increased 25.24 16.55 42 14645 82949 110491663
Intestinal metastasis 25.03 16.55 7 14680 542 110574070
Crystal arthropathy 24.89 16.55 6 14681 258 110574354
Cholelithiasis 24.74 16.55 36 14651 63386 110511226
Arthropathy 24.59 16.55 89 14598 287433 110287179
Injection site hypertrophy 24.33 16.55 5 14682 102 110574510
Cardiac valve sclerosis 24.15 16.55 5 14682 106 110574506
Injection site injury 24.14 16.55 8 14679 1096 110573516
Infection 24.07 16.55 9 14678 362191 110212421
Menstrual disorder 23.90 16.55 12 14675 4772 110569840
Sepsis 23.74 16.55 7 14680 327339 110247273
Blood cholesterol abnormal 23.56 16.55 11 14676 3735 110570877
Persecutory delusion 23.52 16.55 13 14674 6278 110568334
Headache 23.26 16.55 198 14489 882179 109692433
Blood testosterone decreased 23.13 16.55 10 14677 2838 110571774
Polyp 22.73 16.55 15 14672 9965 110564647
Gastrointestinal pain 22.68 16.55 16 14671 11844 110562768
Pyrexia 22.64 16.55 54 14633 898211 109676401
IIIrd nerve paralysis 22.30 16.55 8 14679 1389 110573223
Product administration error 22.12 16.55 26 14661 37191 110537421
Feeling abnormal 21.85 16.55 63 14624 180648 110393964
Ovarian rupture 21.69 16.55 4 14683 45 110574567
Thyroid disorder 21.66 16.55 18 14669 16951 110557661
Pituitary tumour recurrent 21.52 16.55 5 14682 183 110574429
Hepatic enzyme increased 21.28 16.55 8 14679 320884 110253728
Camptocormia 21.23 16.55 6 14681 482 110574130
Fibrosis 21.17 16.55 13 14674 7629 110566983
Mastitis 20.83 16.55 9 14678 2549 110572063
Encephalocele 20.82 16.55 4 14683 57 110574555
Cortisol free urine increased 20.27 16.55 4 14683 66 110574546
Lactose intolerance 20.13 16.55 9 14678 2767 110571845
Hair disorder 19.59 16.55 7 14680 1202 110573410
Wheezing 19.36 16.55 5 14682 255225 110319387
High density lipoprotein decreased 19.14 16.55 11 14676 5722 110568890
Adjacent segment degeneration 18.95 16.55 3 14684 12 110574600
Pleural effusion 18.70 16.55 59 14628 177650 110396962
Retroperitoneal fibrosis 18.61 16.55 6 14681 754 110573858
Abdominal discomfort 18.51 16.55 102 14585 393756 110180856
Panic disorder 18.23 16.55 9 14678 3452 110571160
Mitral valve sclerosis 18.02 16.55 5 14682 376 110574236
Adrenal disorder 18.00 16.55 8 14679 2424 110572188
Autoimmune thyroiditis 17.97 16.55 11 14676 6423 110568189
Metastases to pelvis 17.94 16.55 6 14681 846 110573766
Adrenal insufficiency 17.91 16.55 25 14662 42365 110532247
Bone cancer 17.88 16.55 8 14679 2462 110572150
Trichoglossia 17.75 16.55 6 14681 874 110573738
Movement disorder 17.72 16.55 23 14664 36381 110538231
Libido increased 17.67 16.55 8 14679 2531 110572081
Nocturia 17.60 16.55 16 14671 16974 110557638
Nervousness 17.50 16.55 23 14664 36828 110537784
Hand deformity 17.11 16.55 4 14683 218502 110356110
Crying 17.09 16.55 19 14668 25609 110549003
Dementia 16.98 16.55 21 14666 31652 110542960
Contraindicated product administered 16.77 16.55 6 14681 248261 110326351
Hemianopia 16.74 16.55 8 14679 2860 110571752

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02CB03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Prolactine inhibitors
ATC N04BC06 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA CS M0007652 Ergolines
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:51065 dopamine agonist
CHEBI has role CHEBI:74518 anti-obesity agent
MeSH PA D000978 Antiparkinson Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018726 Anti-Dyskinesia Agents
FDA EPC N0000175827 Ergot Derivative

Related Drugs by ATC class:

G02CB Prolactine inhibitors 5 drugs
bromocriptinelisuridemetergolinequinagolideterguride
N04BC Dopamine agonists 8 drugs
apomorphinebromocriptinedihydroergocryptinepergolidepiribedilpramipexoleropinirolerotigotine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperprolactinemia indication 237662005 DOID:12700
Prevention of ovarian hyperstimulation syndrome indication
Heart valve disorder contraindication 368009 DOID:4079
Severe pre-eclampsia contraindication 46764007
Retroperitoneal fibrosis contraindication 49120005
Fibrosis of lung contraindication 51615001 DOID:3770
Fibrosis of pericardium contraindication 194965002
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Hypertensive urgency contraindication 443482000
Occlusive Vascular Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.83 acidic
pKa2 13.48 acidic
pKa3 7.88 Basic
pKa4 5.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.20 IUPHAR CHEMBL
Alpha-2A adrenergic receptor GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 2A GPCR AGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 2B GPCR Ki 8.85 CHEMBL
5-hydroxytryptamine receptor 2C GPCR AGONIST Ki 6.20 IUPHAR
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 6.50 IUPHAR
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 7.10 IUPHAR
D(3) dopamine receptor GPCR AGONIST Ki 9.10 IUPHAR
D(1B) dopamine receptor GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.30 IUPHAR
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.10 IUPHAR
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
D(4) dopamine receptor GPCR AGONIST Ki 7.30 IUPHAR
Alpha-1D adrenergic receptor GPCR Ki 6.78 PDSP
D(1A) dopamine receptor GPCR AGONIST Ki 6.70 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.22 PDSP

External reference:

IDSource
4021014 VUID
N0000148483 NUI
D00987 KEGG_DRUG
134895 RXNORM
C0107994 UMLSCUI
CHEBI:3286 CHEBI
CHEMBL1201087 ChEMBL_ID
D000077465 MESH_DESCRIPTOR_UI
DB00248 DRUGBANK_ID
37 IUPHAR_LIGAND_ID
5860 INN_ID
LL60K9J05T UNII
54746 PUBCHEM_CID
4317 MMSL
6425 MMSL
73532 MMSL
d04112 MMSL
109139002 SNOMEDCT_US
386979007 SNOMEDCT_US
4021014 VANDF
005446 NDDF
LL60K9J05T INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 0093-5420 TABLET 0.50 mg ORAL ANDA 27 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 23155-823 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3157 TABLET 0.50 mg ORAL ANDA 27 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3951 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-5834 TABLET 0.50 mg ORAL ANDA 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-6596 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-7642 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50742-118 TABLET 0.50 mg ORAL ANDA 31 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50742-118 TABLET 0.50 mg ORAL ANDA 31 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 59762-1005 TABLET 0.50 mg ORAL NDA AUTHORIZED GENERIC 29 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 64380-202 TABLET 0.50 mg ORAL ANDA 14 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 69238-2693 TABLET 0.50 mg ORAL ANDA 21 sections
CABERGOLINE HUMAN PRESCRIPTION DRUG LABEL 1 70069-824 TABLET 0.50 mg ORAL ANDA 13 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 70512-860 TABLET 0.50 mg ORAL ANDA 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 83085-003 TABLET 0.50 mg ORAL ANDA 25 sections